The DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.
G-CSF and GM-CSF in Neutropenia
Open accessAbstract
G-CSF and GM-CSF are used widely to promote the production of granulocytes or APCs. The U.S. Food and Drug Administration approved G-CSF (filgrastim) for the treatment of congenital and acquired neutropenias and for mobilization of peripheral hematopoietic progenitor cells for stem cell transplantation. A polyethylene glycol–modified form of G-CSF is approved for the treatment of neutropenias. Clinically significant neutropenia, rendering an individual immunocompromised, occurs when their number is <1500/μl. Current guidelines recommend their use when the risk for febrile neutropenia is >20%. GM-CSF (sargramostim) is approved for neutropenia associated with stem cell transplantation. Because of its promotion of APC function, GM-CSF is being evaluated as an immunostimulatory adjuvant in a number of clinical trials. More than 20 million persons have benefited worldwide, and >$5 billion in sales occur annually in the United States.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neutrophil recruitment and function in health and inflammation
Kolaczkowska, E., & Kubes, P. (2013) · Nature Reviews Immunology · doi:10.1038/nri3399 · Cited by 5,472
BODEY, G. P., BUCKLEY, M., SATHE, Y. S., & FREIREICH, E. J. (1966) · Annals of Internal Medicine · doi:10.7326/0003-4819-64-2-328 · Cited by 2,469
Smith, T. J., Khatcheressian, J., Lyman, G. H., Ozer, H., Armitage, J. O., Balducci, L., Bennett, C. L., Cantor, S. B., Crawford, J., Cross, S. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4451 · Cited by 1,636
Citron, M. L., Berry, D. A., Cirrincione, C., Hudis, C., Winer, E. P., Gradishar, W. J., Davidson, N. E., Martino, S., Livingston, R., Ingle, J. N., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.081 · Cited by 1,564
Asymmetric and symmetric stem-cell divisions in development and cancer
Morrison, S. J., & Kimble, J. (2006) · Nature · doi:10.1038/nature04956 · Cited by 1,410
Crawford, J., Ozer, H., Stoller, R., Johnson, D., Lyman, G., Tabbara, I., Kris, M., Grous, J., Picozzi, V., Rausch, G., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199107183250305 · Cited by 1,390
Souza, L., Boone, T., Gabrilove, J., Lai, P., Zsebo, K., Murdock, D., Chazin, V., Bruszewski, J., Lu, H., Chen, K., et al. (1986) · Science · doi:10.1126/science.232.4746.61 · Cited by 1,266
Wong, G. G., Witek, J. S., Temple, P. A., Wilkens, K. M., Leary, A. C., Luxenberg, D. P., Jones, S. S., Brown, E. L., Kay, R. M., Orr, E. C., et al. (1985) · Science · doi:10.1126/science.3923623 · Cited by 1,194
Pulmonary Alveolar Proteinosis
Rosen, S. H., Castleman, B., Liebow, A. A., Enzinger, F. M., & Hunt, R. T. N. (1958) · New England Journal of Medicine · doi:10.1056/nejm195806052582301 · Cited by 1,150
Ozer, H., Armitage, J. O., Bennett, C. L., Crawford, J., Demetri, G. D., Pizzo, P. A., Schiffer, C. A., Smith, T. J., Somlo, G., Wade, J. C., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.20.3558 · Cited by 1,044
Cited by
Delivery technologies for cancer immunotherapy
Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,607
Tumour-associated neutrophils in patients with cancer
Shaul, M. E., & Fridlender, Z. G. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0222-4 · Cited by 1,023
GM-CSF: From Growth Factor to Central Mediator of Tissue Inflammation
Becher, B., Tugues, S., & Greter, M. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.026 · Cited by 593
Side-effect management of chimeric antigen receptor (CAR) T-cell therapy
Schubert, M.-L., Schmitt, M., Wang, L., Ramos, C. A., Jordan, K., Müller-Tidow, C., & Dreger, P. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.478 · Cited by 491
GM-CSF, IL-3, and IL-5 Family of Cytokines: Regulators of Inflammation
Dougan, M., Dranoff, G., & Dougan, S. K. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.022 · Cited by 458
Kalakonda, N., Maerevoet, M., Cavallo, F., Follows, G., Goy, A., Vermaat, J. S. P., Casasnovas, O., Hamad, N., Zijlstra, J. M., Bakhshi, S., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30120-4 · Cited by 339
Tumor-associated neutrophils and neutrophil-targeted cancer therapies
Que, H., Fu, Q., Lan, T., Tian, X., & Wei, X. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188762 · Cited by 312
GM-CSF: A Double-Edged Sword in Cancer Immunotherapy
Kumar, A., Taghi Khani, A., Sanchez Ortiz, A., & Swaminathan, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.901277 · Cited by 265
The neutrophil: constant defender and first responder
Fine, N., Tasevski, N., McCulloch, C. A., Tenenbaum, H. C., & Glogauer, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.571085 · Cited by 115
Zhong, Y., Pouliot, M., Downey, A.-M., Mockbee, C., Roychowdhury, D., Wierzbicki, W., & Authier, S. (2021) · International Journal of Radiation Biology · doi:10.1080/09553002.2019.1673499 · Cited by 52
Innate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response
Mercer, D. K., & O'Neil, D. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02177 · Cited by 50
Metadata
- Authors
- Mehta, H. M., Malandra, M., & Corey, S. J.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-08
- Volume
- 195
- Issue
- 4
- Pages
- 1341-1349
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2135137305
- Cited by
- 363
- References
- 97
- FWCI
- 9.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.